Heparin is frequently used to treat ischaemic cerebrovascular disease. The comnplications of heparin therapy are well described and include haemorrhage, thrombocytopenia, which is rarely associated with arterial thrombosis, and osteoporosis. The consequences ofterminating heparin therapy are not well known. Experimental studies have demonstrated thrombosis after heparin withdrawal. Although an intravenous heparin bolus inhibited thrombus formation in the extracorporeal circulation of pigs, compared to untreated controls, the tendency for thrombosis was enhanced 4-5 hours later.' Similarly Ashwin2 found that rats had a higher incidence of jugular venous thrombosis four hours after an intravenous heparin injection than after intravenous saline. These experimental findings seem to have clinical relevance Alvarez Sabin et al3 described a patient with infarction of the internal capsule who subsequently developed a cerebellar infarct three days after stopping heparin. Systemic embolisation after inadvertent interruption of heparin treatment has been reported,4 and we recently observed several patients on heparin for transient ischaemic attacks (TIA) who developed cerebral infarcts soon after heparin was stopped. These experimental and clinical observations suggest that stopping heparin might predispose to thromboembolism and prompted us to examine our records systematically to determine the frequency of clinical deterioration following termination of heparin treatment. To investigate the hypothesis that stopping heparin without replacement increases the risk for an event, we determined the number ofpatients who had an event during the 24 hours before and after heparin was stopped in the replacement and no-replacement groups. A I-tailed Fisher exact test was used for these analyses based on the hypothesis suggested by experimental studies and our anecdotal experience that stopping heparin without replacement increased the risk of an event. Twenty four hours was chosen as the time frame for comparison between the groups for several reasons. First, experimental evidence suggests the greatest risk of enhanced thrombosis occurs within six hours after stopping heparin. Also, adequate follow up information was not available on many patients for longer than 24 hours after stopping heparin. Replacement patients receiving antiplatelet agents and non-replacement patients were often discharged from the hospital 24 hours after heparin was stopped.
Methods

Results
In the 68 months ofthe study period, 401 patients were given heparin for TIA/RIND or ischaemic stroke. Some TIA patients received heparin because they had multiple attacks. The majority of patients with RIND or stroke who were given heparin had either a cardiac source of emboli, a partial deficit or progressive signs. We excluded 23 patients from the analysis because the relevant portions of their charts could not be located. We have no reason to suspect that the excluded patients have clinical features that differ from the patients included in the study. Of the 378 remaining patients, 216 were in the replacement group (183 received'warfarin and 33 antiplatelet agents) and 162 were in the no-replacement group. All patients had CT soon after admission, and none of these initial scans demonstrated haemorrhage or mass lesions.
The replacement and no replacement groups were similar in age, sex, diagnosis and stroke severity (table  1) . Replacement patients, however, were treated significantly longer (median 7 days, range 1-43 days) than no-replacement patients (median 4 days, range 05-l9 days; p < 0.01, Wilcoxon). This discrepancy probably reflects the reasons for stopping heparin in the two groups. Heparin was discontinued in all but seven replacement patients because the treatment course was considered complete, whereas this was true of only one third of no-replacement patients (table 2) . Heparin was stopped in most ofthe remaining patients before a procedure or because of treatment complications. The percentage of patients with an event on heparin was comparable in the non-replacement (34/ 145, 23%) and replacement groups (42/215, 20%). We excluded eighteen patients (17 in the no-replacement group and 1 in the replacement group) with potential nonthrombotic explanations for events on heparin including cerebral haemorrhage, seizures, hypotension, bradycardia, syncope, endarectomy, or respiratory arrest.
A striking feature about the events during heparin events occurred in the no-replacement group 24 hours after stopping heparin (10/143, 7%) than in the previous 24 hour (3/143, 2%, p = 0-04). Nineteen patients in the no-replacement group who had events after stopping heparin were omitted from the above analyses because they had potential explanations for the events such as cerebral haemorrhage, endarterectomy, herniation, and encephalopathy following coronary artery surgery.
Discussion
Several potential limitations of our study need to be considered. One concern is its retrospective nature. While prospective, controlled trials are better suited than retrospective analyses to assess cause and effect relationships, they are not always practical. A prospective design of this study would require half the patients to stop receiving further antithrombotic therapy after their course of heparin was completed. This is unacceptable medical practice as in many patients continued anticoagulation with warfarin is indicated. Even if a prospective trial is ethically feasible, another consideration would be whether the potential clinical significance justifies the time and expense of the study. In this case, it would be difficult to justify a prospective study of sufficient size to determine whether stopping heparin without replacement antithrombotic therapy predisposes patients to further events if only 7% of such patients experience these events. For these reasons, we do not believe a prospective study to examine the risk of stopping heparin will be carried out. Selection bias is a potential source of error in any retrospective study. Clearly we could not identify all the factors that could be important in influencing thrombotic events. In terms of the conclusions, however, the issue is not whether these variables were identified and matched between the two groups but whether for whatever reason one group was more susceptible to thrombotic events. If, for example, noreplacement patients were more unstable than replacement patients, they would be more likely to have events under any circumstance than replacement patients. Our results, however, do not demonstrate a difference in the clinical condition of the two groups. When the percentage of patients who had an event on heparin was analysed as an objective measure of clinical stability, the numbers were similar for replacement patients (20%), no-replacement patients (23%) and no-replacement patients with events after stopping heparin (20%) . A further consideration is that the difference in the length oftherapy between the two groups may be a confounding variable. Since events occurring during heparin treatment are concentrated in the first four days, one might expect that noreplacement patients who were treated for a shorter duration (four days) than replacement patients (seven days) might be more likely to have an event whether heparin was stopped or not. Alternatively, a longer duration of heparin therapy may somehow be protective, in which case replacement patients would be expected to have fewer events than no-replacement patients, since they were treated for longer. To address this problem we analysed the number of events occurring 24 hours before stopping heparin in both no-replacement and replacement patients and found no statistical difference. However, we found significantly more events 24 hours after heparin was stopped compared to the previous 24 hours on heparin in no-replacement patients. There was no such difference in replacement patients. These results suggest that the difference in duration of heparin treatment between the two groups did not affect the results.
Therefore, although the groups may not be perfectly comparable, our results do not suggest that noreplacement patients are more susceptible to events than replacement patients.
The most plausible cause for the events that occur after stopping heparin is that the thrombotic tendency which is held in check during heparin treatment is allowed to continue when the drug is stopped. Alternatively the underlying cerebral thrombotic process may actually be facilitated by stopping heparin. Stopping heparin, experimentally, has been associated with an enhanced tendency for thrombosis.34 Possible mechanisms for potentiation of thrombosis after heparin withdrawal include decreased antithrombin III or elevated factor VIII, both of which have been associated with thromboembolic disease"'0 and reported to occur during heparin therapy." 2 While the clinical events we measured (TIA, stroke or worsening of a stroke deficit) are frequently associated with thromboembolic processes, all can occur by other mechanisms. We excluded patients, most of them in the no-replacement group, with possible non-thrombotic explanations for events such as hypotension, herniation, arrhythmia, or seizures. The events occurring after heparin withdrawal in the five stroke patients (table 3) are not readily explained by cerebral oedema. None of the five patients had severe strokes, which are often associated with clinically significant oedema. Available evidence also suggests that cerebral oedema is maximal two to four days after infarction. ' 
